Clinical puzzle: Barrett's oesophagus

DMM Disease Models and Mechanisms

Volumn 1, Issue 1, 2008, Pages 26-31

  Di Pietro, Massimiliano ^a   Peters, Christopher J ^a   Fitzgerald, Rebecca C ^a  

^a HUTCHISON MRC RESEARCH CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; BARRETT ESOPHAGUS; CANCER GRADING; CANCER RISK; CELL DIFFERENTIATION; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DYSPLASIA; EARLY DIAGNOSIS; ENDOSCOPY; ESOPHAGUS CANCER; GASTROESOPHAGEAL REFLUX; GENETIC PREDISPOSITION; HUMAN; INTESTINE METAPLASIA; NONHUMAN; PRIORITY JOURNAL; SAMPLING ERROR; ADENOCARCINOMA; ANIMAL; BIOLOGICAL MODEL; CELL TRANSFORMATION; ESOPHAGUS TUMOR; GENETICS; PATHOLOGY;

ANIMALIA;

ADENOCARCINOMA; ANIMALS; BARRETT ESOPHAGUS; BIOLOGICAL MARKERS; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; EARLY DIAGNOSIS; ESOPHAGEAL NEOPLASMS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MODELS, BIOLOGICAL;

EID: 64249099859     PISSN: 17548403     EISSN: 17548411     Source Type: Journal    
DOI: 10.1242/dmm.000273     Document Type: Article

References (46)

1. Arber, N., Lightdale, C., Rotterdam, H., Han, K. H., Sgambato, A., Yap, E., Ahsan, H., Finegold, J., Stevens, P. D., Green, P. H. et al. (1996). Increased expression of the cyclin D1 gene in Barrett's esophagus. Cancer Epidemiol. Biomarkers Prev. 5, 457-459. (Pubitemid 26182660)
2. Bani-Hani, K., Martin, I. G., Hardie, L. J., Mapstone, N., Briggs, J. A., Forman, D. and Wild, C. P. (2000). Prospective study of cyclin D1 overexpression in Barrett's esophagus: association with increased risk of adenocarcinoma. J. Natl. Cancer Inst. 92, 1316-1321. (Pubitemid 30660591)
3. Bergman, J. J. (2005). Endoscopic treatment of highgrade intraepithelial neoplasia and early cancer in Barrett oesophagus. Best Pract. Res. Clin. Gastroenterol. 19, 889-907. (Pubitemid 43033438)
4. Bollschweiler, E., Wolfgarten, E., Gutschow, C. and Holscher, A. H. (2001). Demographic variations in the rising incidence of esophageal adenocarcinoma in white males. Cancer 92, 549-555. (Pubitemid 32735190)
5. Brindle, K. (2008). New approaches for imaging tumour responses to treatment. Nat. Rev. Cancer 8, 94-107. (Pubitemid 351161320)
6. Buttar, N. S., Wang, K. K., Anderson, M. A., Dierkhising, R. A., Pacifico, R. J., Krishnadath, K. K. and Lutzke, L. S. (2002a). The effect of selective cyclooxygenase-2 inhibition in Barrett's esophagus epithelium: an in vitro study. J. Natl. Cancer Inst. 94, 422-429.
7. Buttar, N. S., Wang, K. K., Leontovich, O., Westcott, J. Y., Pacifico, R. J., Anderson, M. A., Krishnadath, K. K., Lutzke, L. S. and Burgart, L. J. (2002b). Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology 122, 1101-1112. (Pubitemid 34267291)
8. Canto, M. I., Setrakian, S., Willis, J. E., Chak, A., Petras, R. E. and Sivak, M. V. (2001). Methylene blue staining of dysplastic and nondysplastic Barrett's esophagus: an in vivo and ex vivo study. Endoscopy 33, 391-400. (Pubitemid 32586443)
9. Casson, A. G., Zheng, Z., Evans, S. C., Geldenhuys, L., van Zanten, S. V., Veugelers, P. J., Porter, G. A. and Guernsey, D. L. (2005). Cyclin D1 polymorphism (G870A) and risk for esophageal adenocarcinoma. Cancer 104, 730-739. (Pubitemid 41113671)
10. Casson, A. G., Zheng, Z., Porter, G. A. and Guernsey, D. L. (2006). Genetic polymorphisms of microsomal epoxide hydroxylase and glutathione S-transferases M1, T1 and P1, interactions with smoking, and risk for esophageal (Barrett) adenocarcinoma. Cancer Detect. Prev. 30, 423-431. (Pubitemid 44750414)
11. Chang, C. L., Lao-Sirieix, P., Save, V., De La Cueva Mendez, G., Laskey, R. and Fitzgerald, R. C. (2007). Retinoic acid-induced glandular differentiation of the oesophagus. Gut 56, 906-917. (Pubitemid 46999073)
12. Conio, M., Cameron, A. J., Romero, Y., Branch, C. D., Schleck, C. D., Burgart, L. J., Zinsmeister, A. R., Melton, L. J., 3rd and Locke, G. R., 3rd (2001). Secular trends in the epidemiology and outcome of Barrett's oesophagus in Olmsted County, Minnesota. Gut 48, 304-309.
13. Corder, A. P., Jones, R. H., Sadler, G. H., Daniels, P. and Johnson, C. D. (1996). Heartburn, oesophagitis and Barrett's oesophagus in self-medicating patients in general practice. Br. J. Clin. Pract. 50, 245-248. (Pubitemid 126813831)
14. Crane, S. J., Richard Locke, G., 3rd, Harmsen, W. S., Diehl, N. N., Zinsmeister, A. R., Joseph Melton, L., 3rd, Romero, Y. and Talley, N. J. (2007). The changing incidence of oesophageal and gastric adenocarcinoma by anatomic sub-site. Aliment. Pharmacol. Ther. 25, 447-453.
15. Curvers, W. L., Singh, R., Song, L. M., Wolfsen, H. C., Ragunath, K., Wang, K., Wallace, M. B., Fockens, P. and Bergman, J. J. (2008). Endoscopic tri-modal imaging for detection of early neoplasia in Barrett's oesophagus: a multi-centre feasibility study using high-resolution endoscopy, autofluorescence imaging and narrow band imaging incorporated in one endoscopy system. Gut 57, 167-172. (Pubitemid 351158041)
16. di Martino, E., Hardie, L. J., Wild, C. P., Gong, Y. Y., Olliver, J. R., Gough, M. D. and Bird, N. C. (2007). The NAD(P)H:quinone oxidoreductase I C609T polymorphism modifies the risk of Barrett esophagus and esophageal adenocarcinoma. Genet. Med. 9, 341-347.
17. Fernando, H. C., Luketich, J. D., Buenaventura, P. O., Perry, Y. and Christie, N. A. (2002). Outcomes of minimally invasive esophagectomy (MIE) for highgrade dysplasia of the esophagus. Eur. J. Cardiothorac. Surg. 22, 1-6. (Pubitemid 34743704)
18. Fitzgerald, R. C. (2006). Molecular basis of Barrett's oesophagus and oesophageal adenocarcinoma. Gut 55, 1810-1820.
19. Fortun, P. J., Anagnostopoulos, G. K., Kaye, P., James, M., Foley, S., Samuel, S., Shonde, A., Badreldin, R., Campbell, E., Hawkey, C. J. et al. (2006). Acetic acidenhanced magnification endoscopy in the diagnosis of specialized intestinal metaplasia, dysplasia and early cancer in Barrett's oesophagus. Aliment. Pharmacol. Ther. 23, 735-742. (Pubitemid 43344592)
20. Frese, K. K. and Tuveson, D. A. (2008). Maximizing mouse cancer models. Nat. Rev. Cancer 7, 645-658.
21. Galipeau, P. C., Li, X., Blount, P. L., Maley, C. C., Sanchez, C. A., Odze, R. D., Ayub, K., Rabinovitch, P. S., Vaughan, T. L. and Reid, B. J. (2007). NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma. PLoS Med. 4, e67. (Pubitemid 46354447)
22. Geddert, H., Zeriouh, M., Wolter, M., Heise, J. W., Gabbert, H. E. and Sarbia, M. (2002). Gene amplification and protein overexpression of c-erb-b2 in Barrett carcinoma and its precursor lesions. Am. J. Clin. Pathol. 118, 60-66. (Pubitemid 34734253)
23. Gerson, L. B., Shetler, K. and Triadafilopoulos, G. (2002). Prevalence of Barrett's esophagus in asymptomatic individuals. Gastroenterology 123, 461-467. (Pubitemid 34827190)
24. Ibrahim, N. B. (2000). ACP. Best Practice No 155. Guidelines for handling oesophageal biopsies and resection specimens and their reporting. J. Clin. Pathol. 53, 89-94.
25. Izzo, J. G., Wu, T. T., Wu, X., Ensor, J., Luthra, R., Pan, J., Correa, A., Swisher, S. G., Chao, C. K., Hittelman, W. N. et al. (2007). Cyclin D1 guanine/adenine 870 polymorphism with altered protein expression is associated with genomic instability and aggressive clinical biology of esophageal adenocarcinoma. J. Clin. Oncol. 25, 698-707. (Pubitemid 350002926)
26. Kerkhof, M., van Dekken, H., Steyerberg, E. W., Meijer, G. A., Mulder, A. H., de Bruine, A., Driessen, A., ten Kate, F. J., Kusters, J. G., Kuipers, E. J. et al. (2007). Grading of dysplasia in Barrett's oesophagus: substantial interobserver variation between general and gastrointestinal pathologists. Histopathology 50, 920-927.
27. Lao-Sirieix, P., Lovat, L. and Fitzgerald, R. C. (2007). Cyclin A immunocytology as a risk stratification tool for Barrett's esophagus surveillance. Clin. Cancer Res. 13, 659-665. (Pubitemid 46225374)
28. Leedham, S. J., Preston, S. L., McDonald, S. A., Elia, G., Bhandari, P., Poller, D., Harrison, R., Novelli, M. R., Jankowski, J. A. and Wright, N. A. (2008). Individual crypt genetic heterogeneity and the origin of metaplastic glandular epithelium in human Barrett's oesophagus. Gut 27 Feb [Epub ahead of print].
29. Lovat, L. B., Johnson, K., Mackenzie, G. D., Clark, B. R., Novelli, M. R., Davies, S., O'Donovan, M., Selvasekar, C., Thorpe, S. M., Pickard, D. et al. (2006). Elastic scattering spectroscopy accurately detects high grade dysplasia and cancer in Barrett's oesophagus. Gut 55, 1078-1083. (Pubitemid 44085671)
30. Murray, L., Sedo, A., Scott, M., McManus, D., Sloan, J. M., Hardie, L. J., Forman, D. and Wild, C. P. (2006). TP53 and progression from Barrett's metaplasia to oesophageal adenocarcinoma in a UK population cohort. Gut 55, 1390-1397. (Pubitemid 44476779)
31. Oda, D., Savard, C. E., Eng, L., Sekijima, J., Haigh, G. and Lee, S. P. (1998). Reconstituted human oral and esophageal mucosa in culture. In Vitro Cell. Dev. Biol. Anim. 34, 46-52. (Pubitemid 29069393)
32. Okawa, T., Michaylira, C. Z., Kalabis, J., Stairs, D. B., Nakagawa, H., Andl, C. D., Johnstone, C. N., Klein- Szanto, A. J., El-Deiry, W. S., Cukierman, E. et al. (2007). The functional interplay between EGFR overexpression, hTERT activation, and p53 mutation in esophageal epithelial cells with activation of stromal fibroblasts induces tumor development, invasion, and differentiation. Genes Dev. 21, 2788-2803. (Pubitemid 350070724)
33. Pepe, M. S., Etzioni, R., Feng, Z., Potter, J. D., Thompson, M. L., Thornquist, M., Winget, M. and Yasui, Y. (2001). Phases of biomarker development for early detection of cancer. J. Natl. Cancer Inst. 93, 1054-1061. (Pubitemid 32717537)
34. Playford, R. J. (2006). New British Society of Gastroenterology (BSG) guidelines for the diagnosis and management of Barrett's oesophagus. Gut 55, 442.
35. Powell, J., McConkey, C. C., Gillison, E. W. and Spychal, R. T. (2002). Continuing rising trend in oesophageal adenocarcinoma. Int. J. Cancer 102, 422-427. (Pubitemid 35265884)
36. Redon, R., Ishikawa, S., Fitch, K. R., Feuk, L., Perry, G. H., Andrews, T. D., Fiegler, H., Shapero, M. H., Carson, A. R., Chen, W. et al. (2006). Global variation in copy number in the human genome. Nature 444, 444-454. (Pubitemid 44809057)
37. Ronkainen, J., Aro, P., Storskrubb, T., Johansson, S. E., Lind, T., Bolling-Sternevald, E., Vieth, M., Stolte, M., Talley, N. J. and Agreus, L. (2005). Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology 129, 1825-1831. (Pubitemid 41772961)
38. Sampliner, R. E. (2002). Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am. J. Gastroenterol. 97, 1888-1895. (Pubitemid 34906832)
39. Schulmann, K., Sterian, A., Berki, A., Yin, J., Sato, F., Xu, Y., Olaru, A., Wang, S., Mori, Y., Deacu, E. et al. (2005). Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk. Oncogene 24, 4138-4148. (Pubitemid 40897058)
40. Shaheen, N. J., Crosby, M. A., Bozymski, E. M. and Sandler, R. S. (2000). Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology 119, 333-338.
41. Sharma, V. K., Wang, K. K., Overholt, B. F., Lightdale, C. J., Fennerty, M. B., Dean, P. J., Pleskow, D. K., Chuttani, R., Reymunde, A., Santiago, N. et al. (2007). Balloon-based, circumferential, endoscopic radiofrequency ablation of Barrett's esophagus: 1-year follow-up of 100 patients. Gastrointest. Endosc. 65, 185-195. (Pubitemid 46157125)
42. Shirvani, V. N., Ouatu-Lascar, R., Kaur, B. S., Omary, M. B. and Triadafilopoulos, G. (2000). Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: Ex vivo induction by bile salts and acid exposure. Gastroenterology 118, 487-496. (Pubitemid 30140846)
43. Sirieix, P. S., O'Donovan, M., Brown, J., Save, V., Coleman, N. and Fitzgerald, R. C. (2003). Surface expression of minichromosome maintenance proteins provides a novel method for detecting patients at risk for developing adenocarcinoma in Barrett's esophagus. Clin. Cancer Res. 9, 2560-2566. (Pubitemid 36842097)
44. Solaymani-Dodaran, M., Logan, R. F., West, J., Card, T. and Coupland, C. (2004). Risk of oesophageal cancer in Barrett's oesophagus and gastro-oesophageal reflux. Gut 53, 1070-1074. (Pubitemid 38961957)
45. Younes, M. (2005). Is the incidence of esophageal adenocarcinomas in patients with Barrett's esophagus really overestimated? Gastroenterology 129, 2125- 2126; author reply 2126.
46. Younes, M., Ertan, A., Lechago, L. V., Somoano, J. R. and Lechago, J. (1997). p53 Protein accumulation is a specific marker of malignant potential in Barrett's metaplasia. Dig. Dis. Sci. 42, 697-701. (Pubitemid 27196015)